Sex- and age-specific trends in prescription medication use, 2005–2025: a nationwide repeated cross-sectional study
- 1Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark; Corresponding author. Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense M 5230, Denmark.
- 2Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark
- 3Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Abstract
Background: Previous studies have documented higher medication consumption among females than males; however contemporary sex-based differences across age and therapeutic classes remain poorly characterized. Methods: We used the Danish National Prescription Registry to identify all prescriptions redeemed by Danish adults in 2005, 2015 and 2025, assessing overall medication use by sex and age. For the 30 most prescribed therapeutic classes, age-adjusted rate ratios (aRRs) with 95% confidence intervals (CI) were estimated to compare use between sexes. Polypharmacy (≥ five medications redeemed within a calendar year) was also assessed by sex and age groups. Findings: In 2025, females accounted for 52% of total medication consumption (1.98 billion Defined Daily Doses (DDDs) among females vs. 3.82 billion DDDs overall), down from 60% (1.17 billion vs. 1.96 billion DDDs) in 2005. This female excess was confined to early adulthood; from age 55 onward, male consumption exceeded that of females. While some of the higher medication use reflected a higher prevalence of certain conditions among females (e.g., thyroid disorders, osteoporosis, depression), females also exhibited a higher use of mental health medications, including antipsychotics, and, newly in 2025, ADHD medications (aRR 1.25; 95%CI 1.16–1.34). Males more frequently used cardiovascular therapies (antithrombotic agents (0.64; 0.62–0.66), insulins (0.67; 0.65–0.69)). However, the historical male cardiovascular predominance was challenged in 2025: thiazide diuretics (1.19; 1.16–1.22) and non-insulin glucose-lowering drugs were more prescribed to females (1.08; 1.01–1.16). Polypharmacy was more common among females in early adulthood but converged after age 65. Interpretation: Sex-based differences in overall medication use have narrowed over time. There is a need for continued monitoring of persistent and emerging sex differences in prescribing. Funding: No specific funding.
Related
- Prescription-Duration Patterns of Outpatient Macrolide Use in Participating Community Pharmacies in Tokyo, Japan: A 24-Month Repeated Cross-Sectional Study
- BMI distribution and sex- and grade-specific trends in primary school health surveillance records in Xi’an, China, 2014–2024: a repeated cross-sectional study
- Medication and health-related outcomes by prescription lengths: A systematic review
- Self-reported prescription medication use and polypharmacy following physical combat injury in the UK: the ADVANCE cohort study
- Patterns and Predictors of Repeated Medication Nonadherence in Glaucoma: A Population-Based Study
BibTeX
@article{roland2026agespecific,
title = {{Sex- and age-specific trends in prescription medication use, 2005–2025: a nationwide repeated cross-sectional study}},
author = {Noémie Roland and Martin Thomsen Ernst and Jesper James Linde and Lotte Rasmussen and Anton Pottegård},
journal = {The Lancet Regional Health. Europe},
year = {2026},
month = oct,
doi = {10.1016/j.lanepe.2026.101909},
url = {https://doi.org/10.1016/j.lanepe.2026.101909},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Sex- and age-specific trends in prescription medication use, 2005–2025: a nationwide repeated cross-sectional study
AU - Noémie Roland
AU - Martin Thomsen Ernst
AU - Jesper James Linde
AU - Lotte Rasmussen
AU - Anton Pottegård
PY - 2026
DA - 2026/10/23
JO - The Lancet Regional Health. Europe
DO - 10.1016/j.lanepe.2026.101909
UR - https://doi.org/10.1016/j.lanepe.2026.101909
AB - Background: Previous studies have documented higher medication consumption among females than males; however contemporary sex-based differences across age and therapeutic classes remain poorly characterized. Methods: We used the Danish National Prescription Registry to identify all prescriptions redeemed by Danish adults in 2005, 2015 and 2025, assessing overall medication use by sex and age. For the 30 most prescribed therapeutic classes, age-adjusted rate ratios (aRRs) with 95% confidence intervals (CI) were estimated to compare use between sexes. Polypharmacy (≥ five medications redeemed within a calendar year) was also assessed by sex and age groups. Findings: In 2025, females accounted for 52% of total medication consumption (1.98 billion Defined Daily Doses (DDDs) among females vs. 3.82 billion DDDs overall), down from 60% (1.17 billion vs. 1.96 billion DDDs) in 2005. This female excess was confined to early adulthood; from age 55 onward, male consumption exceeded that of females. While some of the higher medication use reflected a higher prevalence of certain conditions among females (e.g., thyroid disorders, osteoporosis, depression), females also exhibited a higher use of mental health medications, including antipsychotics, and, newly in 2025, ADHD medications (aRR 1.25; 95%CI 1.16–1.34). Males more frequently used cardiovascular therapies (antithrombotic agents (0.64; 0.62–0.66), insulins (0.67; 0.65–0.69)). However, the historical male cardiovascular predominance was challenged in 2025: thiazide diuretics (1.19; 1.16–1.22) and non-insulin glucose-lowering drugs were more prescribed to females (1.08; 1.01–1.16). Polypharmacy was more common among females in early adulthood but converged after age 65. Interpretation: Sex-based differences in overall medication use have narrowed over time. There is a need for continued monitoring of persistent and emerging sex differences in prescribing. Funding: No specific funding.
SN - 2666-7762
ER -